Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
5,755
Views
5
CrossRef citations to date
0
Altmetric
Gastroenterology
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany
Aditya Sardesaia Evidera Inc., San Francisco, CA, USACorrespondence[email protected]
, Axel Dignassb Agaplesion Markus Hospital, Frankfurt/Main, Germany
https://orcid.org/0000-0002-9724-054X
Peter Quonc Evidera Inc., Bethesda, MD, USA
, Sandra Mileva Evidera Inc., San Francisco, CA, USA
, Joseph C. Cappellerid Pfizer Inc, Groton, CT, USA
https://orcid.org/0000-0001-9586-0748
Agnes Kissere Pfizer Germany GmbH, Berlin, Germany
, Irene Modestof Pfizer Inc, New York, NY, USA
& Puza P. Sharmaf Pfizer Inc, New York, NY, USA
show all
Pages 279-290
|
Received 12 Nov 2020, Accepted 22 Jan 2021, Published online: 24 Feb 2021
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.